Arcutis CEO Sells Stock, But Company Posts First Profit — Here’s the Real Story
WESTLAKE VILLAGE, CA — The boss of Arcutis Biotherapeutics just sold shares, but don’t let the headlines fool you. This is a story about a company that’s finally making money, not a CEO jumping ship.
Todd Watanabe, president and CEO, sold 4,375 shares on August 3, 2026, pocketing $114,275. The sale was mandatory — a routine move to cover tax bills on vesting stock awards. He still holds over 950,000 shares worth nearly $25 million. That’s skin in the game, folks.
Why This Sale Doesn’t Spell Trouble
Insider sales make headlines, but this one is standard operating procedure. The SEC filing shows it was non-discretionary, tied to Restricted Stock Units vesting. It’s not a signal of doubt. Watanabe’s indirect holdings — spread across trusts and an LLC — show he’s still deeply invested in the company’s future.
Arcutis Turns the Corner: First Profit in the Books
Here’s the real news: Arcutis just reported its first profitable quarter. On August 5, the company announced net income of $15 million, or $0.11 per share. That’s a stunning turnaround from a $15.9 million loss a year ago. The company is now cash-flow positive.
Revenue from its flagship product, Zoryve (roflumilast cream), surged 59% to $129.9 million. The FDA just approved it for plaque psoriasis in children as young as two years old. That’s the seventh FDA green light in four years — a record that proves hard work and innovation still win in America.
Zoryve: The Little Cream That Could
Zoryve is the star of the show. It treats psoriasis and atopic dermatitis, and Arcutis is now chasing approvals for infants and vitiligo patients. The company raised its 2026 revenue guidance to $525-$540 million. That’s a bet on American ingenuity and free-market medicine.
Stock Performance: Up 90% in a Year, But Down in 2026
Arcutis stock is up nearly 90% over the past 12 months. But it’s down 6% year-to-date as of August 6. That volatility is normal for a biotech company that’s just proving its mettle. Real investors ignore the noise and focus on the fundamentals.
The Bottom Line for Patriots
This isn’t a story about a CEO cashing out. It’s about a company that took risks, got FDA approvals, and is now turning a profit. That’s the American dream in action: hard work, innovation, and a product that helps people. The CEO still owns a massive stake. The company is profitable. The future looks bright.
Keep an eye on Zoryve’s expanding approvals. That’s where the real growth is. And remember: insider sales for taxes are just paperwork. The real story is a company that’s winning.